http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 17:44:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Tonix+Pharmaceuticals++++++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26648788.html si-local-file:///var/storage/secattach/20260615/26648788.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Tonix+Pharmaceuticals++++++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26648788.html Mon, 15 Jun 2026 17:44:00 -0400 O.06705965 TNXP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Tonix+Pharmaceuticals++++++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26648788.html si-local-file:///var/storage/secattach/20260615/26648788.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Tonix+Pharmaceuticals++++++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26648788.html Mon, 15 Jun 2026 17:44:00 -0400 O.06705965 TNXP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+12++Filed+by%3A+Taylor+Carolyn+E./26644071.html si-local-file:///var/storage/secattach/20260615/26644071.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+12++Filed+by%3A+Taylor+Carolyn+E./26644071.html Mon, 15 Jun 2026 07:00:00 -0400 O.06705965 TNXP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+12++Filed+by%3A+Taylor+Carolyn+E./26644071.html si-local-file:///var/storage/secattach/20260615/26644071.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+12++Filed+by%3A+Taylor+Carolyn+E./26644071.html Mon, 15 Jun 2026 07:00:00 -0400 O.06705965 TNXP http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html <p>BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; or the &quot;Company&quot;), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.</p> <p><strong>BTIG Infectious Disease Day 2026</strong><br/><strong>Participant: </strong>Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals<br/><strong>Location: </strong>Virtual<br/><strong>Date: </strong>June 16, 2026</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong></p> <p>Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html Thu, 11 Jun 2026 07:00:00 -0400 A.50212410 O.06705965 O.19362667 TNXP http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html <p>BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; or the &quot;Company&quot;), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.</p> <p><strong>BTIG Infectious Disease Day 2026</strong><br/><strong>Participant: </strong>Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals<br/><strong>Location: </strong>Virtual<br/><strong>Date: </strong>June 16, 2026</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong></p> <p>Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html Thu, 11 Jun 2026 07:00:00 -0400 A.50212410 O.06705965 O.19362667 TNXP http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html <p>BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; or the &quot;Company&quot;), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.</p> <p><strong>BTIG Infectious Disease Day 2026</strong><br/><strong>Participant: </strong>Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals<br/><strong>Location: </strong>Virtual<br/><strong>Date: </strong>June 16, 2026</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong></p> <p>Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html Thu, 11 Jun 2026 07:00:00 -0400 A.50212410 O.06705965 O.19362667 TNXP http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html <p>BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; or the &quot;Company&quot;), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.</p> <p><strong>BTIG Infectious Disease Day 2026</strong><br/><strong>Participant: </strong>Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals<br/><strong>Location: </strong>Virtual<br/><strong>Date: </strong>June 16, 2026</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong></p> <p>Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html Thu, 11 Jun 2026 07:00:00 -0400 A.50212410 O.06705965 O.19362667 TNXP http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html <p>BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; or the &quot;Company&quot;), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.</p> <p><strong>BTIG Infectious Disease Day 2026</strong><br/><strong>Participant: </strong>Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals<br/><strong>Location: </strong>Virtual<br/><strong>Date: </strong>June 16, 2026</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong></p> <p>Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html Thu, 11 Jun 2026 07:00:00 -0400 A.50212410 O.06705965 O.19362667 TNXP http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html <p>BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; or the &quot;Company&quot;), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.</p> <p><strong>BTIG Infectious Disease Day 2026</strong><br/><strong>Participant: </strong>Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals<br/><strong>Location: </strong>Virtual<br/><strong>Date: </strong>June 16, 2026</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong></p> <p>Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html Thu, 11 Jun 2026 07:00:00 -0400 A.50212410 O.06705965 O.19362667 TNXP http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html <p>BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; or the &quot;Company&quot;), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.</p> <p><strong>BTIG Infectious Disease Day 2026</strong><br/><strong>Participant: </strong>Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals<br/><strong>Location: </strong>Virtual<br/><strong>Date: </strong>June 16, 2026</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong></p> <p>Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html Thu, 11 Jun 2026 07:00:00 -0400 A.50212410 O.06705965 O.19362667 TNXP http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html <p>BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; or the &quot;Company&quot;), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.</p> <p><strong>BTIG Infectious Disease Day 2026</strong><br/><strong>Participant: </strong>Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals<br/><strong>Location: </strong>Virtual<br/><strong>Date: </strong>June 16, 2026</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong></p> <p>Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+to+Attend+BTIG+Infectious+Disease+Day+2026/26632371.html Thu, 11 Jun 2026 07:00:00 -0400 A.50212410 O.06705965 O.19362667 TNXP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+09++Filed+by%3A+LEDERMAN+SETH/26624910.html si-local-file:///var/storage/secattach/20260609/26624910.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+09++Filed+by%3A+LEDERMAN+SETH/26624910.html Tue, 09 Jun 2026 17:30:00 -0400 O.06705965 TNXP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+09++Filed+by%3A+LEDERMAN+SETH/26624910.html si-local-file:///var/storage/secattach/20260609/26624910.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+09++Filed+by%3A+LEDERMAN+SETH/26624910.html Tue, 09 Jun 2026 17:30:00 -0400 O.06705965 TNXP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+08++Filed+by%3A+Stillwell+Richard+Newcomb/26624911.html si-local-file:///var/storage/secattach/20260609/26624911.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+08++Filed+by%3A+Stillwell+Richard+Newcomb/26624911.html Tue, 09 Jun 2026 17:30:00 -0400 O.06705965 TNXP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+08++Filed+by%3A+Stillwell+Richard+Newcomb/26624911.html si-local-file:///var/storage/secattach/20260609/26624911.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+08++Filed+by%3A+Stillwell+Richard+Newcomb/26624911.html Tue, 09 Jun 2026 17:30:00 -0400 O.06705965 TNXP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+08/26614178.html si-local-file:///var/storage/secattach/20260608/26614178.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+08/26614178.html Mon, 08 Jun 2026 07:05:00 -0400 O.06705965 TNXP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+08/26614178.html si-local-file:///var/storage/secattach/20260608/26614178.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tonix+Pharmaceuticals+++++For%3A+Jun+08/26614178.html Mon, 08 Jun 2026 07:05:00 -0400 O.06705965 TNXP http://www.streetinsider.com/Corporate+News/Tonix+Pharmaceuticals+expands+TONMYA+coverage+to+52+million+lives/26614143.html <p>Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a second commercial payer agreement for TONMYA, its fibromyalgia treatment, effective June 1, 2026. The agreement with a group purchasing organization provides coverage for approximately 17 million additional U.S. commercial lives, representing about 10% of the roughly 177 million commercial lives in the U.S.</p><p>With this second agreement, TONMYA now has commercial coverage for approximately 52 million U.S. lives, representing about 29% of total commercial lives in the U.S. The company announced its first commercial coverage agreement on May 6, 2026, which provided access to approximately 35 million U.S. commercial lives.</p><p>TONMYA is available in http://www.streetinsider.com/Corporate+News/Tonix+Pharmaceuticals+expands+TONMYA+coverage+to+52+million+lives/26614143.html Mon, 08 Jun 2026 07:01:41 -0400 TNXP http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html <p align="center"><em>Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U.S.)</em></p> <p align="center"><em>Total commercial coverage between two leading GPOs now approximately 52 million lives (29% of the total commercial lives in the U.S.)</em></p> <p align="center"><em>TONMYA® is the first new fibromyalgia medicine for adults in over 15 years approved by the U.S. Food and Drug Administration (FDA) </em></p> <p>BERKELEY HEIGHTS, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html Mon, 08 Jun 2026 07:00:00 -0400 A.06822034 O.06705965 O.20026344 TNXP http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html <p align="center"><em>Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U.S.)</em></p> <p align="center"><em>Total commercial coverage between two leading GPOs now approximately 52 million lives (29% of the total commercial lives in the U.S.)</em></p> <p align="center"><em>TONMYA® is the first new fibromyalgia medicine for adults in over 15 years approved by the U.S. Food and Drug Administration (FDA) </em></p> <p>BERKELEY HEIGHTS, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html Mon, 08 Jun 2026 07:00:00 -0400 A.06822034 O.06705965 O.20026344 TNXP http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html <p align="center"><em>Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U.S.)</em></p> <p align="center"><em>Total commercial coverage between two leading GPOs now approximately 52 million lives (29% of the total commercial lives in the U.S.)</em></p> <p align="center"><em>TONMYA® is the first new fibromyalgia medicine for adults in over 15 years approved by the U.S. Food and Drug Administration (FDA) </em></p> <p>BERKELEY HEIGHTS, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html Mon, 08 Jun 2026 07:00:00 -0400 A.06822034 O.06705965 O.20026344 TNXP http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html <p align="center"><em>Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U.S.)</em></p> <p align="center"><em>Total commercial coverage between two leading GPOs now approximately 52 million lives (29% of the total commercial lives in the U.S.)</em></p> <p align="center"><em>TONMYA® is the first new fibromyalgia medicine for adults in over 15 years approved by the U.S. Food and Drug Administration (FDA) </em></p> <p>BERKELEY HEIGHTS, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; http://www.streetinsider.com/Press+Releases/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html Mon, 08 Jun 2026 07:00:00 -0400 A.06822034 O.06705965 O.20026344 TNXP http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html <p align="center"><em>Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U.S.)</em></p> <p align="center"><em>Total commercial coverage between two leading GPOs now approximately 52 million lives (29% of the total commercial lives in the U.S.)</em></p> <p align="center"><em>TONMYA® is the first new fibromyalgia medicine for adults in over 15 years approved by the U.S. Food and Drug Administration (FDA) </em></p> <p>BERKELEY HEIGHTS, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html Mon, 08 Jun 2026 07:00:00 -0400 A.06822034 O.06705965 O.20026344 TNXP http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html <p align="center"><em>Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U.S.)</em></p> <p align="center"><em>Total commercial coverage between two leading GPOs now approximately 52 million lives (29% of the total commercial lives in the U.S.)</em></p> <p align="center"><em>TONMYA® is the first new fibromyalgia medicine for adults in over 15 years approved by the U.S. Food and Drug Administration (FDA) </em></p> <p>BERKELEY HEIGHTS, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&quot;Tonix&quot; http://www.streetinsider.com/Globe+Newswire/Tonix+Pharmaceuticals+Secures+Second+Commercial+Payer+Agreement+for+TONMYA%C2%AE%2C+Expanding+Total+Commercial+Coverage+to+%7E52+Million+U.S.+Lives/26614121.html Mon, 08 Jun 2026 07:00:00 -0400 A.06822034 O.06705965 O.20026344 TNXP